查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
CAR-T细胞疗法的全球市场 - 市场规模，预测，实验，趋势(2025年)
市场调查报告书
商品编码
1609195

CAR-T细胞疗法的全球市场 - 市场规模，预测，实验，趋势(2025年)

Global CAR-T Cell Therapy Market - Market Size, Forecasts, Trials & Trends, 2025
出版日期: | 出版商: BioInformant | 英文 332 Pages | 订单完成后即时交付

价格
简介目录

摘要整理

CAR-T细胞疗法对于癌症患者来说是一种极具前景的治疗方法。这是一种免疫疗法，医生收集免疫细胞，在实验室修改它们，并赋予它们识别和杀死癌细胞的能力。一旦注射到患者体内，细胞就会繁殖并作为 "活药" 保留在体内。

CAR-T疗法的支柱是T细胞。 T 细胞对于免疫系统引导免疫反应和消除被病原体感染的细胞的能力至关重要。 CAR-T 疗法包括从患者身上抽取血液并分离 T 细胞。这些细胞在实验室中使用改良病毒进行基因工程改造，在 T 细胞表面产生嵌合抗原受体 (CAR)。一旦被重新引入患者体内，这种 CAR 就可以让 T 细胞识别并结合癌细胞上的特定抗原，从而消灭它们。

2017年至今，已有11个CAR-T产品商业化。其中七种是美国 FDA 批准的 CAR T 细胞疗法，每种疗法也获得了其他主要医疗市场的批准。

美国FDA认证的7个产品如下列。

  • Kymriah - Novartis宾夕法尼亚大学和共同开发。Novartis销售。
  • Yescarta - Gilead Sciences的子公司Kite Pharma开发。Gilead Sciences销售。
  • Tecartus - Gilead Sciences的子公司Kite Pharma开发。Gilead Sciences销售。
  • Breyanzi - Bristol-Myers Squibb(BMS)所收购的Juno Therapeutics(Celgene的子公司)开发。BMS销售。
  • Abecma - bluebird bioBristol-Myers Squibb(BMS)和共同开发。BMSbluebird 与bio共同销售。
  • Carvykti - Legend Biotech作为Johnson & Johnson的子公司的Janssen Biotech和共同开发。Janssen Biotech和Legend Biotech销售。
  • Aucatzyl - Autolus Therapeutics开发。

此外，Relma-cel和元瑞达两种CAR-T疗法已获得中国NMPA批准。此外，印度 CDSCO 也批准了两种 CAR-T 疗法：NexCAR19 和 Qartemi。

这些批准显示了 CAR-T 市场的快速成长，并对生物技术产业产生了重大影响。併购尤其活跃，新基 (Celgene) 在 2018 年以 90 亿美元收购了 Juno Therapeutics，百时美施贵宝 (BMS) 在 2019 年以 740 亿美元收购了新基 (Celgene)。吉利德以 119 亿美元收购 Kite Pharma 也成为头条新闻。

价值 10 亿美元的 CAR T 细胞治疗市场的成功很大程度上归功于早期治疗在治疗血癌方面的显着效果。然而，CAR-T疗法的下一个重大课题是扩大其在实体肿瘤治疗的应用。目前，市面上所有九种 CAR-T 产品以及近 75% 正在进行的临床试验都采用自体方法（使用患者自己的细胞）。使用供体细胞开发同种异体 CAR-T 疗法预计将创造巨大的市场机会。

CAR-T 疗法的另一个障碍是从血浆分离术（收穫 T 细胞的过程）到交付最终产品的 "静脉到静脉" 时间。由于这个过程可能会延长，通常建议用尽其他治疗选择的末期病人使用 CAR-T 疗法。此外，报销仍然是美国和欧洲的一个主要课题。

本报告调查了全球 CAR-T 细胞治疗市场，并对 CAR-T 细胞治疗现状和 CAR-T 行业状况进行了详细分析。我们还涵盖已批准的 CAR-T 疗法和可能很快商业化的后期临床试验。

目录

第1章 报告概要

第2章 CAR-T细胞疗法:技术开发

  • CAR-T细胞疗法概述
  • CAR-T 开发的演变
  • 造血恶性细胞中存在的抗原
  • 将受体基因插入 T 细胞的工具
  • T 细胞转化为 CAR-T 细胞
  • 11 种市售 CAR-T 疗法：概述
    • Kymriah (tisagenlecleucel)
    • Yescarta (axicabtagene ciloleucel)
    • Tecartus (brexucabtagene autoleucel)
    • Carvykti (ciltacabtagene autoleucel)
    • Abecma (idecabtagene vicleucel)
    • Breyanzi (lisocabtagene maraleucel)
    • Relma-cel (relmacabtagene autoleucel)
    • NexCAR19 (Actalycabtagene autoleucel)
    • Yuanruida (inaticabtagene autoleucel，CNCT19)
    • Qartemi (varnimcabtagene autoleucel)
    • Aucatzyl (obecabtagene autoleucel)
  • CAR-T治疗伴随的毒性

第3章 未来的CAR-T疗法的策略

  • 可切换 CAR (sCAR)
  • 破坏体内CAR-T细胞的自杀基因
  • 瞬时转染
  • 亲和力调整的 CAR
  • 装甲车
  • 从血癌到实体癌症的转变
  • 注重缩短住院时间
  • 专注于发现新抗原
  • 从自体 CAR-T 疗法过渡到同种异体 CAR-T 疗法
  • 面向大众的 CAR-T
  • 一种新的体内 CAR-T 方法
  • 与 mRNA 疫苗组合
  • 与溶瘤病毒组合

第4章 CAR-T开发主要的事件(1989年～2024年)

  • CAR-T 开发时间表
  • CAR-T 疗法实现的 10 个里程碑
  • CAR-T疗法产品的现状
  • 未来 CAR-T 之星
  • CAR-T疗法针对的癌症患者
  • CAR-T细胞疗法的优势
  • CAR-T细胞疗法的缺点

第5章 CAR-T细胞的可伸缩的製造

  • 临床规模的自体 CAR-T 疗法製造工艺
  • CAR-T细胞製造平台的演变

第6章 CAR-T标的抗原

  • 血癌中的CAR-T标靶抗原
  • 实体肿瘤上的 CAR-T 标靶抗原
  • 临床试验中 CAR-T 细胞标靶的常见抗原

第7章 CAR-T的专利形势

  • CAR-T专利的地理分布
  • CAR-T专利申请量排名前10名的公司
  • 拥有 CAR-T 专利发明的前 10 家公司
  • 拥有 CAR-T 专利的前 10 家公司
  • CAR-T专利的法律地位

第8章 CAR-T的临床试验形势

  • 临床试验中最常见的适应症
  • 正在进行的临床试验的重点
  • 临床试验：依国家分类
  • 研究阶段
  • CAR-T 临床试验：依经费类型划分
  • 临床试验中治疗的造血系统恶性肿瘤类型
  • 使用一个 CAR-T 同时定位
  • 临床试验中使用的 CAR-T 世代类型
  • 针对实体肿瘤的CAR-T临床试验
  • CAR-T 研究的分布：以使用的 SeFv 类型分类
  • CAR-T 测试的分布：依所使用的载具类型
  • 实体肿瘤CAR-T研究的地理分布
  • 临床试验中的 CAR-T 标靶生物标记
  • 临床试验中CAR-T结构的完善

第9章 PUBMED.GOV所发表的CAR-T科学论文

  • 来自 PubMed.gov 的自体和同种异体 CAR-T 疗法的文章
  • PubMed.gov 上有关 CAR-T 治疗血癌和实体瘤的文章（2013 年至 2024 年 3 月）
  • 关于第五代 CAR 的 PubMed 文章
  • NIH 为 CAR-T 研究提供资金

第10章 CAR-T的资金筹措形势

  • CAR-T 领域的创投（2014 年至 2024 年 3 月）
  • 投资 CAR-T 公司的 IPO 融资（2014 年-2024 年 3 月）
  • CAR-T 许可协议
  • CAR-T 合作协议
  • CAR-T 併购 (M&A) 交易（2015 年至 2024 年 3 月）
  • CAR-T 资金概览

第11章 与CAR-T治疗的成本偿付

  • 新的支付模式
  • 美国 CAR-T 疗法的报销
  • 欧洲 CAR-T 疗法的费用
  • 亚洲 CAR-T 疗法的费用和报销

第12章 CAR-T治疗的血液癌症

  • 急性淋巴性白血病（ALL）
  • 瀰漫性大 B 细胞淋巴瘤 (DLBCL)
  • 套细胞淋巴瘤 (MCL)
  • 多发性骨髓瘤 (MM)
  • 滤泡性淋巴瘤
  • 血癌治疗的庞大费用

第13章 市场分析

  • CAR-T细胞疗法的普及性（2017-2023）
    • 目前 CAR-T 细胞疗法的全球市场：依产品分类
  • CAR-T细胞治疗产品全球市场预测（2024-2032年）
    • CAR-T 疗法的全球市场：按地区划分
    • CAR-T 疗法的全球市场：依适应症分类
  • CAR-T 疗法治疗血癌的课题与机会
    • 访问障碍
    • CD19 以外的目标
    • 对 CAR-T 疗法的抗药性
    • 生产时间
    • 自体 CAR-T 与同种异体 CAR-T

第14章 CAR-T企业:概要

  • 2seventy bio
  • Abintus Bio, Inc.
  • AffyImmune Therapeutics, Inc.
  • Aleta BioTherapeutics
  • Allogene Therapeutics
  • Anixa Biosciences, Inc.
  • Arbele, Ltd.
  • Arcellx
  • Atara Biotherapeutics
  • Aurora BioPharma
  • Autolus Therapeutics plc
  • AvenCell Europe GmbH
  • Beam Therapeutics, Inc.
  • Bellicum Pharmaceuticals
  • BioNTech
  • Biosceptre
  • Bluebird bio
  • Bristol Myers Squibb/Celgene Corporation
  • Cabaletta Bio
  • Carina Biotech
  • CARsgen Therapeutics
  • Cartesian Therapeutics
  • CARTherics Pty Ltd.
  • CASI Pharmaceuticals
  • Cellectis
  • Celularity, Inc.
  • Celyad Oncology
  • CRISPR Therapeutics
  • Curocell, Inc.
  • DiaCarta
  • Elicera Therapeutics AB
  • EXUMA Biotech
  • Fate Therapeutics
  • Galapagos NV
  • Gilead Sciences, Inc.
  • Gracell Biotechnologies
  • IASO Biotherapeutics
  • ImmPACT Bio
  • Immuneel Therapeutics, Pvt., Ltd.
  • ImmunoACT
  • Interius BioTherapeutics
  • Juventas Cell Therapy
  • JW Therapeutics
  • Kite Pharma (Gilead)
  • Kyverna Therapeutics
  • Legend Biotech
  • Leucid Bio
  • Luminary Therapeutics, Inc.
  • Lyell Immunopharma, Inc.
  • March Biosciences
  • MaxCyte, Inc.
  • Minerva Biotechnologies Corporation
  • Mustang Bio
  • Noile-Immune Biotech
  • Novartis AG
  • Oncternal Therapeutics
  • Oxford Biomedica plc
  • PeproMene Bio, Inc.
  • Poseida Therapeutics, Inc.
  • Precigen, Inc.
  • Prescient Therapeutics
  • ProMab Biotechnologies, Inc.
  • SOTIO Biotech BV
  • Syngene International, Ltd.
  • Synthekine
  • TC BioPharm
  • T-CURX
  • Umoja Biopharma
  • ViTToria Biotherapeutics
  • Vor Biopharma
  • Wugen
  • WuXi Advanced Therapies
  • Xenetic Biosciences
  • Xyphos Biosciences, Inc.

图的索引

表的索引

简介目录

EXECUTIVE SUMMARY

CAR-T cell therapy is a remarkably promising treatment for cancer patients. It is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to identify and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as "living drugs."

The backbone of CAR-T therapy is T-cells, which are essential to the immune system's ability to direct immune responses and eliminate cells infected by pathogens. For CAR-T therapy, blood is drawn from the patient, and T-cells are isolated. These cells are then genetically engineered in the laboratory using a modified virus, which enables the T-cells to produce chimeric antigen receptors (CARs) on their surface. Once reintroduced into the patient's body, these CARs allow the T-cells to recognize and bind to specific antigens on cancer cells, leading to their destruction.

From 2017 to today, 11 CAR-T products have reached commercialization. Of these, seven are U.S. FDA-approved CAR-T cell therapies, each of which have received approvals in other major healthcare markets as well.

The seven U.S. FDA approved products include:

  • Kymriah - Developed by Novartis in collaboration with the University of Pennsylvania. Marketed by Novartis.
  • Yescarta - Developed by Kite Pharma, a subsidiary of Gilead Sciences. Marketed by Gilead Sciences.
  • Tecartus - Developed by Kite Pharma, a subsidiary of Gilead Sciences. Marketed by Gilead Sciences.
  • Breyanzi - Developed by Juno Therapeutics (a Celgene company), which was acquired by Bristol-Myers Squibb (BMS). Marketed by BMS.
  • Abecma - Developed by bluebird bio in partnership with Bristol-Myers Squibb (BMS). Marketed by BMS in collaboration with bluebird bio.
  • Carvykti - Developed by Legend Biotech in partnership with Janssen Biotech, a subsidiary of Johnson & Johnson. Marketed by Janssen Biotech and Legend Biotech.
  • Aucatzyl - Developed and marketed by Autolus Therapeutics.

Additionally, two CAR-T therapies have been approved by the Chinese National Medical Products Administration (NMPA): Relma-cel and Yuanruida. Two CAR-T therapies have also been approved by the Indian Central Drugs Standard Control Organisation (CDSCO): NexCAR19 and Qartemi.

These approvals highlight the rapid growth of the CAR-T market, which is having a significant impact on the biotech industry. Mergers and acquisitions have been particularly active, with Celgene acquiring Juno Therapeutics for $9 billion in 2018, and Bristol-Myers Squibb (BMS) purchasing Celgene for $74 billion by 2019. Gilead's $11.9 billion acquisition of Kite Pharma also made headlines.

The billion-dollar CAR-T cell therapy market owes much of its success to the early therapies' impressive effectiveness in treating blood cancers. However, the next major challenge for CAR-T therapies will be expanding their use to treat solid tumors. Currently, all nine marketed CAR-T products, along with nearly 75% of ongoing clinical trials, utilize an autologous approach (using the patient's own cells). Developing allogeneic CAR-T therapies-using donor cells-will open up critical market opportunities.

Another hurdle for CAR-T therapies is the "vein-to-vein" time-the time between apheresis (the process of collecting the T-cells) and the delivery of the final product. This process can be lengthy, so CAR-T therapies are typically recommended for end-stage patients who have exhausted other treatment options. Additionally, reimbursement remains a significant challenge in the U.S. and Europe.

The industry is working to overcome these challenges. Several CAR-T companies are using advanced gene-transfer techniques to introduce CARs into T-cells more efficiently. Partnerships are also emerging to develop CRISPR and electroporation technologies to enhance T-cell modification. Additionally, some companies are incorporating "on-off" switches in CAR-T cells to prevent toxicity. Despite progress, achieving success with solid tumors has proven difficult, with clinical trials so far showing low response rates. The focus now is on identifying effective antigens specific to solid tumors.

This report provides detailed analysis of the current state of CAR-T cell therapies and the broader CAR-T industry landscape. It highlights approved CAR-T therapies and late-stage clinical trials that could reach commercialization soon. CAR-T companies, ranging from small startups to billion-dollar giants, are now proliferating in all major healthcare markets worldwide.

Key questions answered in this report include:

  • What are the most targeted antigens for liquid and solid tumors?
  • What developments are anticipated in the CAR-T sector, and what commercial opportunities and patient outcomes will they create?
  • How many CAR-T-related patent publications and granted patents have been issued since 2012?
  • Which countries hold the largest number of CAR-T patents?
  • Which companies have filed the most CAR-T patents?
  • Who are the leading inventors in CAR-T patent filings?
  • How many CAR-T clinical trials have been registered over the past 20 years?
  • Which biomarker antigens are most prominent in the CAR-T clinical trial landscape?
  • What are the most common indications being addressed by CAR-T clinical trials in the U.S. and China?
  • Which companies are leading CAR-T clinical trials?
  • How many deals have been made within the CAR-T sector in recent years?
  • Which promising CAR-T candidates are likely to reach commercialization soon?
  • How are CAR-T therapies reimbursed in the U.S. and Europe?
  • How many automated manufacturing systems are currently available in the global market?
  • What is the current market size for CAR-T cell therapies by geography, product, and indication?
  • What are the future market forecasts for CAR-T cell therapies by geography, product, and indication?
  • What barriers, risks, and opportunities exist for growth in the global CAR-T industry?
  • Who are the major companies developing CAR-T cell therapies, what are their core technologies, and what products do they have in development?

This global strategic report reveals:

  • Global CAR-T Cell Therapy Market Size, segmented by Product, Geography, and Indication, with future market size forecasts through 2032
  • In-depth coverage of approved CAR-T products, including regulatory approvals, pricing, reimbursement, and market penetration
  • Analysis of clinical trial activity by type, geography, phase, and sponsor
  • Comprehensive CAR-T patent analysis, including top inventors, patent holders, patent types, geographies, and the most cited patents
  • Overview of CAR-T industry mergers and acquisitions, IPOs, and financing events
  • Examination of strategic partnerships, alliances, and co-commercialization agreements within the CAR-T sector
  • Market trends, future directions, and emerging opportunities
  • Profiles of leading CAR-T competitors in the global marketplace
  • And so much more

TABLE OF CONTENTS

1. REPORT OVERVIEW

  • 1.2. Statement of the Report
  • 1.2. Executive Summary
  • 1.3. Introduction

2. CAR-T CELL THERAPY: TECHNOLOGY DEVELOPMENT

  • 2.1. CAR-T Cell Therapy Overview
  • 2.2. Evolution of CAR-T Development
    • 2.2.1. The CAR-T Cell Therapy Technology Progression
      • 2.2.1.1. First Generation CARs
      • 2.2.1.2. The Second Generation CARs
      • 2.2.1.3. Third Generation CARs
      • 2.2.1.4. Fourth Generation CARs
      • 2.2.1.5. Fifth Generation CARs
      • 2.2.1.6. CAR Constructs in the FDA Approved CAR-T Cell Products
  • 2.3. Antigens Present on Hematological Malignant Cells
  • 2.4. Tools for Inserting Receptor Genes into T Cells
  • 2.5. Transforming T Cells into CAR-T Cells
  • 2.6. The 11 CAR-T Therapies Available in the Market: A Brief Overview
    • 2.6.1. Kymriah (tisagenlecleucel)
      • 2.6.1.1. Indication
      • 2.6.1.2. Product Description & Mechanism of Action
      • 2.6.1.3. Manufacturing
      • 2.6.1.4. Dosage Composition
      • 2.6.1.5. Approval History
      • 2.6.1.6. Market
      • 2.6.1.7. Competition
    • 2.6.2. Yescarta (axicabtagene ciloleucel)
      • 2.6.2.1. Indication
      • 2.6.2.2. Product Description & Mechanism of Action
      • 2.6.2.3. Manufacturing Process of Yescarta
      • 2.6.2.4. Dosage Composition
      • 2.6.2.5. Approval History
      • 2.6.2.7. Sales Revenues
      • 2.6.2.8. Competitors
    • 2.6.3. Tecartus (brexucabtagene autoleucel)
      • 2.6.3.1. Indication
      • 2.6.3.2. Product Description & Mechanism of Action
      • 2.6.3.3. Tecartus Manufacturing Process
      • 2.6.3.4. Dosage Composition
      • 2.6.3.5. Approval History
      • 2.6.3.6. Sales Revenues
      • 2.6.3.7. Competitors
    • 2.6.4. Carvykti (ciltacabtagene autoleucel)
      • 2.6.4.1. Indication
      • 2.6.4.2. Product Description & Mechanism of Action
      • 2.6.4.3. Manufacturing Process of Carvykti
      • 2.6.4.4. Dosage & Composition
      • 2.6.4.5. Approval History
      • 2.6.4.6. Sales Revenues
      • 2.6.4.7. Competition
    • 2.6.5. Abecma (idecabtagene vicleucel)
      • 2.6.5.1. Indication
      • 2.6.5.2. Product Description and Mechanism of Action
      • 2.6.5.3. Manufacturing of Abecma
      • 2.6.5.4. Dosage & Composition
      • 2.6.5.5. Approval History
      • 2.6.5.6. Sales Revenues
      • 2.6.5.7. Competitors
    • 2.6.6. Breyanzi (lisocabtagene maraleucel)
      • 2.6.6.1. Indication
      • 2.6.6.2. Product Description & Mechanism of Action
      • 2.6.6.3. Manufacturing
      • 2.6.6.4. Breyanzi Dosage & Composition
      • 2.6.6.5. Approval History
      • 2.6.6.6. Sales Revenues
    • 2.6.7. Relma-cel (relmacabtagene autoleucel)
    • 2.6.8. NexCAR19 (Actalycabtagene autoleucel)
    • 2.6.9. Yuanruida (inaticabtagene autoleucel; CNCT19)
    • 2.6.10. Qartemi (varnimcabtagene autoleucel)
      • 2.6.10.1. Indication & Dosage
      • 2.6.10.2. Product Description & Mechanism of Action
      • 2.6.10.3. Manufacturing
    • 2.6.11. Aucatzyl (obecabtagene autoleucel)
      • 2.6.11.1. Product Description
      • 2.6.11.2. Indication & Dosage
      • 2.6.11.3. Mechanism of Action
      • 2.6.11.4. Manufacturing
      • 2.6.11.5. Competitor
  • 2.7. Toxicities Associated with CAR-T Treatment

3. STRATEGIES FOR FUTURE CAR-T THERAPIES

  • 3.1. Switchable CARs (sCARs)
  • 3.2. Suicide Genes to Destroy CAR-T Cells in vivo
  • 3.3. Transient Transfection
  • 3.4. Affinity-Tuned CARs
  • 3.5. Armored CARs
  • 3.6. Shifts from Liquid Cancers to Solid Tumors
  • 3.7. Focus on Shortening Hospital Stay
  • 3.8. Focus on Discovering New Antigens
  • 3.9. Shifting from Autologous to Allogeneic CAR-T Therapies
  • 3.10. CAR-T for the Masses
  • 3.11. New In Vivo CAR-T Approaches
  • 3.12. Combination with mRNA Vaccine
  • 3.13. Combination with Oncolytic Virus

4. MAJOR EVENTS DURING THE DEVELOPMENT OF CAR-T, 1989-2024

  • 4.1. CAR-T Development Timeline
  • 4.2. Top Ten Milestones Crossed by CAR-T Therapy
    • 4.2.1. First Pediatric Patient to Receive CAR-T Therapy
    • 4.2.2. CAR-T Granted Breakthrough Therapy Designation
    • 4.2.3. The Beginning of CAR-T Development to Combat Solid Cancers
    • 4.2.4. First CRISPR CAR-T Built
    • 4.2.5. The First Two CAR-T Approvals by FDA
    • 4.2.6. The First Two CAR-T Approvals by EMA
    • 4.2.7. Approval of Tecartus, Breyanzi and Abecma
    • 4.2.8. NMPA Approval of Relma-cel (Carteyva)
    • 4.2.9. Approval of Carvykti
    • 4.2.10. Approval of NexCAR19 (actalycabtagene autoleucel)
    • 4.2.11. Approval of Yuanruida (inaticabtagene autoleucel)
    • 4.2.12. Approval of Qartemi (varnimcabtagene autoleucel)
    • 4.2.13. Approval of Aucatzyl (obecabtagene autoleucel)
  • 4.3. Current Status of CAR-T Therapy Products
  • 4.4. The Upcoming CAR-T Stars
    • 4.4.1. ALLO-501
    • 4.4.2. CTX-110
    • 4.4.3. UCART19
    • 4.4.4. AUT01
    • 4.4.5. JCARH125
    • 4.4.6. PBCAR20A
    • 4.4.7. UCART123
    • 4.4.8. PRGN-3006
    • 4.4.9. UCART22
    • 4.4.10. UCARTCS1
  • 4.5. Cancer Population Addressed by CAR-T Therapy
  • 4.6. Advantages of CAR-T Cell Therapy
  • 4.7. Disadvantages of CAR-T Cell Therapy

5. SCALABLE MANUFACTURING OF CAR-T CELLS

  • 5.1. The Manufacturing Process of Clinical-Scale Autologous CAR-T Therapies
  • 5.2. The Evolution of CAR-T Cell Manufacturing Platforms
    • 5.2.1. Open vs. Closed Systems
    • 5.2.2. Manual Processing vs. Automation
    • 5.2.3. Autologous vs. Allogeneic CAR-T Manufacturing
    • 5.2.4. Operating Expenses in Autologous CAR-T Manufacturing
    • 5.2.5. Operating Expenses in Allogeneic CAR-T Manufacturing

6. CAR-T TARGET ANTIGENS

  • 6.1. CAR-T Target Antigens in Hematological Cancers
  • 6.2. CAR-T Target Antigens on Solid Tumors
  • 6.3. Common Antigens Targeted by CAR-T Cells in Clinical Trials
    • 6.3.1. Cluster Differentiation 19 (CD19)
    • 6.3.2. Mesothelin
    • 6.3.3. Beta Cell Maturation Agent (BCMA)
    • 6.3.4. GD2
    • 6.3.5. Glypican-3 (GPC3)
    • 6.3.6. Cluster Differentiation-22 (CD22)

7. CAR-T PATENT LANDSCAPE

  • 7.1. Geographical Distribution of CAR-T Patents
  • 7.2. Top Ten Applicants of CAR-T Patents
  • 7.3. Top Ten Inventors of CAR-T Patents
  • 7.4. Top Ten Owners of CAR-T Patents
  • 7.5. Legal Status of CAR-T Patents

8. CAR-T CLINICAL TRIAL LANDSCAPE

  • 8.1. Most Addressed Indications in Clinical Trials
  • 8.2. Current Focus of Ongoing Clinical Trials
  • 8.3. Clinical Trial by Country
  • 8.4. Phase of Studies
  • 8.5. CAR-T Clinical Trials by Funding Type
  • 8.6. Types of Hematological Malignancies Addressed in Clinical Trials
  • 8.7. Simultaneous Targets by one CAR-T
  • 8.8. CAR-T Generation Types used in Clinical Trials
  • 8.9. CAR-T Clinical Trials Focusing on Solid Cancers
  • 8.10. Distribution of CAR-T Trials by Type of SeFv Used
  • 8.11. Distribution of CAR-T Trials by Type of Vectors Used
  • 8.12. Geographical Distribution of CAR-T Studies in Solid Tumors
    • 8.12.1. CAR-T Solid Tumor Clinical Trials by Phase of Study
    • 8.12.2. Funding Types in CAR-T Solid Tumor Clinical Trials
    • 8.12.3. Solid Tumor Types in Clinical Trials
  • 8.13. CAR-T Targeted Biomarkers in Clinical Trials
    • 8.13.1. CAR-T Targeted Indications in the U.S. Clinical Trials
    • 8.13.2. Indications Addressed by CAR-T Clinical Trials in China
    • 8.13.3. Liquid Cancers vs. Solid Cancers in CAR-T Clinical Trials
    • 8.13.4. CAR-T Clinical Trial Sponsor Companies and Institutions in the U.S.
    • 8.13.5. CAR-T Clinical Trial Sponsor Companies and Institutions in China
    • 8.13.6. CAR-T Trial Sponsor Companies and Institutions in Other Countries
  • 8.14. Improved CAR-T Constructs in Clinical Trials
    • 8.14.1. CAR-T with PD1Fc
    • 8.14.2. CAR-T with Truncated EFGR
    • 8.14.3. CAR-T with IL7 and CCL 19
    • 8.14.4. CAR-T with PD1/CD28 Switch Receptor
    • 8.14.5. CAR-T with PD1 shRNA Expressing Cassette
    • 8.14.6. CAR-T with CTLA-4/PD-1 Antibody
    • 8.14.7. CAR-T with PD-1 Antibodies

9. PUBLISHED CAR-T SCIENTIFIC PAPERS IN PUBMED.GOV

  • 9.1. PubMed.gov Papers on Autologous and Allogeneic CAR-T Therapies
  • 9.2. PubMed.gov Papers on CAR-T for Liquid vs. Solid Cancers, 2013-March 2024
  • 9.3. PubMed Papers on the Five Generation of CARs
  • 9.4. NIH Funding for CAR-T Research

10. CAR-T FUNDING LANDSCAPE

  • 10.1. Venture Capital Funding in CAR-T Sector, 2014to March 2024
    • 10.1.1. Venture Capital Funding for CAR-T Companies by Year, 2014-March 2024
  • 10.2. IPO Funding in Invested in CAR-T Companies, 2014-March 2024
  • 10.3. CAR-T Licensing Deals
  • 10.4. CAR-T Collaboration Deals
  • 10.5. CAR-T Merger and Acquisition (M&A) Deals, 2015-March 2024
  • 10.6. Overview of CAR-T Funding

11. COST OF CAR-T TREATMENT AND REIMBURSEMENT

  • 11.1. New Payment Models
    • 11.1.1. List Price of approved CAR-Ts
    • 11.1.2. Component Cost in addition to Treatment Acquisition Cost
    • 11.1.3. Adverse Event Costs (AEs)
  • 11.2. Reimbursement in the U.S. for CAR-T Therapy
    • 11.2.1. Policy Changes for FY 2024
  • 11.3. Cost of CAR-T Therapies in Europe
    • 11.3.1. Cost Components and Resource Use
    • 11.3.2. Average Total Component Costs for CAR-T Therapy in Former EU-5 and NL
    • 11.3.3. Reimbursement for CAR-T Therapies in Europe
    • 11.3.4. Innovative Reimbursement Schemes in Europe
  • 11.4. Cost & Reimbursement for CAR-T Therapy in Asia
    • 11.4.1. Cost & Reimbursement for CAR-T in Japan
    • 11.4.2. Cost & Reimbursement for CAR-T Therapy in South Korea
    • 11.4.3. Cost & Reimbursement for CAR-T Therapy in Malaysia
    • 11.4.4. Cost & Reimbursement for CAR-T Therapy in Singapore
    • 11.4.5. Cost & Reimbursement for CAR-T Therapy in China
    • 11.4.6. Cost of CAR-T Therapy in India

12. BLOOD CANCERS ADDRESSED BY CAR-T

  • 12.1. Acute Lymphoblastic Leukemia (ALL)
    • 12.1.1. Available Therapies
  • 12.2. Diffuse Large B-Cell Lymphoma (DLBCL)
    • 12.2.1. Available Therapies
  • 12.3. Mantle Cell Lymphoma (MCL)
    • 12.3.1. Available Therapies
  • 12.4. Multiple Myeloma (MM)
    • 12.4.1. Available Therapies
  • 12.5. Follicular Lymphoma
    • 12.5.1. Available Therapies
  • 12.6. The Staggering Cost of Blood Cancer Therapies

13. MARKET ANALYSIS

  • 13.1. Uptake of CAR-T Cell Therapy, 2017-2023
    • 13.1.1. Current Global Market for CAR-T Cell Therapy by Product
  • 13.2. Estimated Global Market for CAR-T Cell Therapy Products, 2024-2032
    • 13.2.1. Global Market for CAR-T Therapy by Geography
    • 13.2.2. Global Market for CAR-T Therapy by Indication
  • 13.3. Challenges & Opportunities for CAR-T Therapies in Blood Cancers
    • 13.3.1. Barriers to Access
    • 13.3.2. Targets other than CD19
    • 13.3.3. Resistance for CAR-T Therapy
    • 13.3.4. Manufacturing Time
    • 13.3.5. Autologous vs. Allogeneic CAR-Ts

14. CAR-T COMPNIES: AN OVERVIEW

  • 14.1 2seventy bio
    • 14.1.1. Abecma (idecabtagene vicleucel)
  • 14.2. Abintus Bio, Inc.
  • 14.3. AffyImmune Therapeutics, Inc.
    • 14.3.1. Affinity-Tuned CARs
      • 14.3.1.1. ICAM-1: AffyImmune's Target Antigen
      • 14.3.1.2. Targeted Indication
  • 14.4. Aleta BioTherapeutics
    • 14.4.1. Aleta's CAR-T Engager Pipeline
  • 14.5. Allogene Therapeutics
    • 14.5.1. AlloCAR-T
      • 14.5.1.1. Manufacturing of AlloCAR-T
  • 14.6. Anixa Biosciences, Inc.
  • 14.7. Arbele, Ltd.
    • 14.7.1. Advanced Cell Therapy
  • 14.8. Arcellx
    • 14.8.1. D-Domain Technology
    • 14.8.2. ddCAR Platform
    • 14.8.3. ARC-SparX Platform
  • 14.9. Atara Biotherapeutics
    • 14.9.1. Technology
    • 14.9.2. Allogeneic CAR-T Programs
  • 14.10. Aurora BioPharma
    • 14.10.1. HER2 Platform
  • 14.11. Autolus Therapeutics plc
    • 14.11.1. Technology
    • 14.11.2. CAR-T Cell Production
    • 14.11.3. Manufacturing
    • 14.11.4. Therapies in Development
      • 14.11.4.1. obe-cel
  • 14.12. AvenCell Europe GmbH
    • 14.12.1. Universal Switchable CAR
    • 14.12.2. Allogeneic Platform
    • 14.12.3. Clinical & Preclinical Pipeline Overview
  • 14.13. Beam Therapeutics, Inc.
    • 14.13.1. BEAM-201
  • 14.14. Bellicum Pharmaceuticals
    • 14.14.1. GoCAR Technology
    • 14.14.2. CaspaCIDe Safety Switch
  • 14.15. BioNTech
    • 14.15.1. BioNTech's Engineered Cell Therapies
    • 14.15.2. BN211
    • 14.15.3. BN212
  • 14.16. Biosceptre
    • 14.16.1. Biosceptre's Unique Target nf2X7
    • 14.16.2. BRiDGECAR Program
  • 14.17. Bluebird bio
    • 14.17.1. Blebird bio's CAR-T Collaborations
    • 14.17.2. Collaboration with BMS
    • 14.17.3. Collaboration with TC BioPharm
    • 14.17.4. Collaboration with Inhibrx
    • 14.17.5. Collaboration with PsiOxus
  • 14.18. Bristol Myers Squibb/Celgene Corporation
    • 14.18.1. Products
      • 14.18.1.1. Abecma (idecabtagene vicleucel)
      • 14.18.1.2. Breyanzi (lisocabtagene maraleucel)
  • 14.19. Cabaletta Bio
    • 14.19.1. CABA Platform
    • 14.19.2. Cabaletta's Pipeline
  • 14.20. Carina Biotech
  • 14.21. CARsgen Therapeutics
    • 14.21.1. CycloCAR-T
    • 14.21.2. THANK-uCAR
    • 14.21.3. LADAR
  • 14.22. Cartesian Therapeutics
    • 14.22.1. mRNA CAR-T Cell Program (RNA Armory)
    • 14.22.2. Pipeline
  • 14.23. CARTherics Pty Ltd.
    • 14.23.1. Autologous CAR-T Cells
  • 14.24. CASI Pharmaceuticals
    • 14.24.1. Yuanruida (inaticabtagene autoleucel; CNCT19)
  • 14.25. Cellectis
    • 14.25.1. TAL nucleases, or TALEN
    • 14.25.2. Gene Editing
    • 14.25.3. PulseAgile Technology
    • 14.25.4. Main Product Candidates
  • 14.26. Celularity, Inc.
    • 14.26.1. P CAR-T
  • 14.27. Celyad Oncology
    • 14.27.1. NKG2D-Based CAR-T Cells
    • 14.27.2. Multispecific CAR
    • 14.27.3. Short Hairpin RNA-based Platform
    • 14.27.4. CAR-T Therapy Development Services
    • 14.27.5. Biomarker Identification and Selection
    • 14.27.6. scFv Generation
    • 14.27.7. CAR-T Gene Packaging and Delivery
    • 14.27.8. Virus Testing Service
    • 14.27.9. CAR Cell in vitro Assay Service
    • 14.27.10. CAR-T Preclinical in vivo Assay
    • 14.27.11. IND Development for CAR-T Cell Therapy
    • 14.27.12. GMP Production for CAR-T Products
    • 14.27.13. CAR-T Clinical Trial Services
  • 14.28. CRISPR Therapeutics
    • 14.28.1. CRISPR Therapeutics' Immuno-Oncology Programs
    • 14.28.2. CRISPR/Cas9-enabled Allogeneic CAR-T Design
  • 14.29. Curocell, Inc.
    • 14.29.1. OVIS Technology
  • 14.30. DiaCarta
    • 14.30.1. Personalized CAR-T Immunotherapy Platform
  • 14.31. Elicera Therapeutics AB
    • 14.31.1. iTANK CAR-T Technology
    • 14.31.2. Elicera's Product Pipeline
  • 14.32. EXUMA Biotech
    • 14.32.1. TMR CAR-T Technology
    • 14.32.2. CCT3 CAR-T
    • 14.32.3. rPOC SC CAR-TaNKs
    • 14.32.4. GCAR "in vivo Cell Therapy"
  • 14.33. Fate Therapeutics
    • 14.33.1. FT819
    • 14.33.2. FT825
  • 14.34. Galapagos NV
  • 14.35. Gilead Sciences, Inc.
    • 14.35.1. CAR-T Products
      • 14.35.1.1. Tecartus (brexucabtagene autoleucel)
      • 14.34.1.2. Yescarta (axicabtagene ciloleucel)
  • 14.36. Gracell Biotechnologies
    • 14.36.1. FasTCAR
    • 14.36.2. TruUCAR
    • 14.36.3. SMART CAR-T
    • 14.36.4. Gracell's Product Pipeline
  • 14.37. IASO Biotherapeutics
    • 14.37.1. Technology Platforms
    • 14.37.2. Fully Human Antibody Discovery Platform
    • 14.37.3. High-Throughput Screening Platform for CAR-T Candidates
    • 14.37.4. Universal CAR-T Technology Platform
    • 14.37.5. CAR-T Manufacturing Technology Platform
    • 14.37.6. IASO's Diverse Product Pipeline
  • 14.38. ImmPACT Bio
    • 14.38.1. CD19/20 Bispecific CAR
    • 14.38.2. TGF-Beta
  • 14.39. Immuneel Therapeutics, Pvt., Ltd.
    • 14.39.1. Immuneel's R&D Roadmap
  • 14.40. ImmunoACT
    • 14.40.1. NexCAR19 (Actalycabtagene autoleucel)
  • 14.41. Interius BioTherapeutics
    • 14.41.1. Core Technology
  • 14.42. Juventas Cell Therapy
    • 14.42.1. Yuanruida (inaticabtagene autoleucel)
  • 14.43. JW Therapeutics
    • 14.43.1. Carteyva (relmacabtagene autoleucel; relma-cel)
  • 14.44. Kite Pharma (Gilead)
    • 14.44.1. Kite's Marketed CAR-T Products
      • 14.44.1.1. Yescarta (axicabtagene ciloleucel)
      • 14.44.1.2. Tecartus (brexucabtagene autoleucel)
    • 14.44.2. Kite's Pipeline Cancer Therapies
  • 14.45. Kyverna Therapeutics
    • 14.45.1. Kyverna's CAR-T Therapy for Autoimmune Diseases
  • 14.46. Legend Biotech
    • 14.46.1. Technology Platforms
      • 14.46.1.1. CAR-T
      • 14.46.1.2. CAR-Gamma-Delta- T
      • 14.46.1.3. CAR-NK
      • 14.46.1.4. Non-Gene-Editing Universal CAR-T
    • 14.46.2. Product Pipeline
  • 14.47. Leucid Bio
    • 14.47.1. Leucid's Lateral CAR-Platform
    • 14.47.2. LEU011 - NKG2D CAR-T Cell Therapy
    • 14.47.3. T2, Gamma-Delta- T-Cells for Off-The-Shelf Therapy
    • 14.47.4. T4 Immunotherapy
    • 14.47.5. Novel Manufacturing Platform
  • 14.48. Luminary Therapeutics, Inc.
    • 14.48.1. Allogeneic Gamma 2.0+ Platform
    • 14.48.2. Non-Viral Gene Modification Process
    • 14.48.3. Split Co-Stim Dual CAR
    • 14.48.4. Ligand-Based CAR to Target Three Antigens
    • 14.48.5. Product Pipeline
  • 14.49. Lyell Immunopharma, Inc.
    • 14.49.1. Technology
      • 14.49.1.1. Gen-R Technology
      • 14.49.1.2. Epi-R Technology
    • 14.49.2. Lyell's Product Pipeline
  • 14.50. March Biosciences
    • 14.50.1. MB-105
    • 14.50.2. March Biosciences' Pipeline
  • 14.51. MaxCyte, Inc.
    • 14.51.1. Technology: Flow Electroporation
    • 14.51.2. MaxCyte's Electroporation Systems
      • 14.51.2.1. ATx
      • 14.51.2.2. GTx
      • 14.51.2.3. STx
      • 14.51.2.4. VLx
  • 14.52. Minerva Biotechnologies Corporation
    • 14.52.1. CAR-T (huMNC2-CAR44)
  • 14.53. Mustang Bio
    • 14.53.1. Mustang's CAR-T Focus
  • 14.54. Noile-Immune Biotech
    • 14.54.1. PRIME CAR-T
  • 14.55. Novartis AG
    • 14.55.1. The Pioneer in CAR-T
    • 14.55.2. Kymriah (tisagenlecleucel)
    • 14.55.3. T-Charge Platform
      • 14.55.3.1. Phase I YTB323 Clinical Study
      • 14.55.3.2. Phase I PHE 885 Clinical Study
  • 14.56. Oncternal Therapeutics
    • 14.56.1. ONCT-808
  • 14.57. Oxford Biomedica plc
    • 14.57.1. LentiVector Platform
    • 14.57.2. inAAVate Platform
    • 14.57.3. CDMO Services
  • 14.58. PeproMene Bio, Inc.
    • 14.58.1. BAFFR CAR-T Cells
  • 14.59. Poseida Therapeutics, Inc.
    • 14.59.1. Poseida's Genetic Engineering Platforms
    • 14.59.2. PiggyBac Platform for Insertion
    • 14.59.3. Cas-CLOVER Platform for Editing
    • 14.59.4. Poseida's CAR-T Product Candidates
  • 14.60. Precigen, Inc.
    • 14.60.1. UltraCAR-T
    • 14.60.2. Sleeping Beauty System
    • 14.60.3. UltraPorator System
    • 14.60.4. Product Pipeline
  • 14.61. Prescient Therapeutics
    • 14.61.1. OmniCAR
    • 14.61.2. CellPryme
  • 14.62. ProMab Biotechnologies, Inc.
    • 14.62.1. ProMab's CAR-T Cells
    • 14.62.2. ProMab's Services
    • 14.62.3. ProMab's Preclinical and Clinical Study Services
  • 14.63. SOTIO Biotech BV
    • 14.63.1. BOXR Technology
    • 14.63.2. BOXR1030
  • 14.64. Syngene International, Ltd.
    • 14.64.1. CAR-T Services
  • 14.65. Synthekine
    • 14.65.1. STK-009 + SYNCAR-001
  • 14.66. TC BioPharm
    • 14.66.1. Gamma Delta T Cells
    • 14.66.2. Cell Banks
    • 14.66.3. Co-Stim CAR-T
    • 14.66.4. Product Pipeline
      • 14.66.4.1. OmnImmune
    • 14.66.5. CAR-T Programs
  • 14.67. T-CURX
    • 14.67.1. Technologies
  • 14.68. Umoja Biopharma
    • 14.68.1. Umoja's Technology Platforms
      • 14.68.1.1. VivoVec in vivo Gene Delivery
      • 14.68.1.2. RACR-Induced Cytotoxic Lymphocytes (iCIL)
      • 14.68.1.3. RACR/CAR: in vivo Cell Programming
      • 14.68.1.4. TumorTag: Universal CAR Tumor Targeting
  • 14.69. ViTToria Biotherapeutics
    • 14.69.1. Senza5
    • 14.69.2. VIPER-101
  • 14.70. Vor Biopharma
    • 14.70.1. Vor Biopharma's Approach
  • 14.71. Wugen
  • 14.72. WuXi Advanced Therapies
    • 14.72.1. WuXi's Closed Process CAR-T manufacturing
  • 14.73. Xenetic Biosciences
    • 14.73.1. DNase-based Oncology Platform
  • 14.74. Xyphos Biosciences, Inc.
    • 14.74.1. ACCEL & UDC Technology
    • 14.74.2. convertibleCAR
    • 14.74.3. Universal Donor Cells

INDEX OF FIGURES

  • FIGURE 2.1: The Basic Structure of a T cell
  • FIGURE 2.2: Binding of a T cell on to an Infected Cell
  • FIGURE 2.3: Components of a CAR-T cell
  • FIGURE 2.4: The Three Domains of a CAR
  • FIGURE 2.5: The first Generation CARs
  • FIGURE 2.6: Second Generation CARs
  • FIGURE 2.7: Third Generation CARs
  • FIGURE 2.8: Fourth Generation CARs
  • FIGURE 2.9: Fifth Generation CARs
  • FIGURE 2.10: CAR Constructs in the FDA Approved CAR-T Cell Products
  • FIGURE 2.11: Antigens Present on Normal and Cancer Cells
  • FIGURE 2.12: Preparation and Administration of CAR-T cell Therapy
  • FIGURE 2.13: Kymriah in Infusion Bag
  • FIGURE 2.14: Yescarta in Infusion Bag
  • FIGURE 2.15: Tecartus in Infusion Bag
  • FIGURE 2.16: Carvykti in Infusion Bag
  • FIGURE 2.17: Abecma in the Infusion Bag
  • FIGURE 2.18: Breyanzi in Package
  • FIGURE 2.19: Relma-cel Infusion Bag
  • FIGURE 3.1: Switchable CARs [sCARs; Universal CARs]
  • FIGURE 3.2: Action of Suicide Genes
  • FIGURE 3.3: Graphical Abstract for Transient Transfection
  • FIGURE 3.4: A Model of Armored CAR
  • FIGURE 4.1: The Five Generations of CARs
  • FIGURE 5.1: Manufacturing Process of Clinical-Scale Autologous CAR-T Therapies
  • FIGURE 5.2: G-Rex Bioreactors
  • FIGURE 5.3: CliniMACS Prodigy
  • FIGURE 5.4: Scaling Up of Allogeneic CAR-T Cells
  • FIGURE 5.5: Operating Expenses for Autologous CAR-T Manufacturing
  • FIGURE 5.6: Operating Expenses in Allogeneic CAR-T Manufacturing
  • FIGURE 6.1: CAR-T Target Antigens Evaluated in Clinical Trials
  • FIGURE 8.1: CAR-T Clinical Trials by Phase of Study, March 2024
  • FIGURE 8.2: Types of Hematological Malignancies Addressed in Clinical Trials
  • FIGURE 8.3: Studies for Simultaneous Targets by One CAR-T
  • FIGURE 8.4: CAR-T Generation Types used in Clinical Trials
  • FIGURE 8.5: Distribution of CAR-T Trials by Type of SeFv Used
  • FIGURE 8.6: Distribution of CAR-T Trials by Type of Vectors Used
  • FIGURE 8.7: Solid Tumor Types in Clinical Trials, March 2024
  • FIGURE 8.8: Liquid Cancers vs. Solid Cancers in CAR-T Clinical Trials
  • FIGURE 9.1: Number of Published CAR-T Papers on PubMed.gov, 2000-March 2024
  • FIGURE 9.2: PubMed Papers on Autologous vs. Allogeneic CAR-T Therapies, 2000-2024
  • FIGURE 9.3: PubMed Papers on CAR-T for Liquid vs. Solid Cancers, 2013-March 2024
  • FIGURE 9.4: PubMed Papers on the Five Generation of CARs
  • FIGURE 10.1: Venture Capital Funding for CAR-T Companies by Year, 2014-March 2024
  • FIGURE 10.2: IPO Invested in CAR-T Companies, 2014-March 2024
  • FIGURE 13.1: Uptake of U.S.FDA-Approved CAR-Ts, 2017-2023
  • FIGURE 13.2: Revenue Generation by CAR-T Therapy by Product, 2017-2023
  • FIGURE 13.3: Estimated Modest Growth of CAR-T Market by Product, 2023-2032
  • FIGURE 13.4: Global Market for CAR-T Products by Geography, 2023-2032
  • FIGURE 13.5: Global Market for CAR-T Therapies by Indication, 2024-2032
  • FIGURE 14.1: Atara's Approach to Allogeneic Cell Therapy
  • FIGURE 14.2: Illustration of CycloCAR-T
  • FIGURE 14.3: Illustration of THANK-uCAR-T
  • FIGURE 14.5: Schematic of Allogeneic P CAR-T with TCR KO
  • FIGURE 14.6: NKG2D-based CAR
  • FIGURE 14.7: Celyad's Multispecific CAR
  • FIGURE 14.8: CRISPR/Cas9-enabled Allogeneic CAR-T Design
  • FIGURE 14.9: FT819
  • FIGURE 14.10: FT825
  • FIGURE 14.11: FasTCAR vs. Conventional CAR-T Manufacturing Time
  • FIGURE 14.12: Action of TruUCAR
  • FIGURE 14.13: SMART CAR-T
  • FIGURE 14.14: CD19/CD20 CAR-T Technology
  • FIGURE 14.15: TGF-Beta- Bispecific CAR Technology
  • FIGURE 14.16: Lateral CAR
  • FIGURE 14.17: T4 T-Cell
  • FIGURE 14.18: Split Co-Stim Dual CAR
  • FIGURE 14.19: Ligand-Based CAR to Target Three Antigens
  • FIGURE 14.20: Natural Killing of CAR-T Cells
  • FIGURE 14.21: ATx
  • FIGURE 14.22: GTx
  • FIGURE 14.23: STx
  • FIGURE 14.24: VLx
  • FIGURE 14.25: Features of PRIME CAR-T Cell Therapy
  • FIGURE 14.26: BAFFR CAR-T Cells
  • FIGURE 14.27: Poseida's PiggyBac Platform for Insertion
  • FIGURE 14.28: Poseida's Cas-CLOVER Platform for Editing
  • FIGURE 14.29: UltraCAR-T Cell
  • FIGURE 14.30: Precigen's Ultraporator System
  • FIGURE 14.31: Prescient's OmniCAR
  • FIGURE 14.32: VIPER-101, the Lead Program of ViTToria
  • FIGURE 14.33: WuXi's Closed Process CAR-T Platform
  • FIGURE 14.34: Convertible CAR Parts
  • FIGURE 14.35: Xyphos' Universal Donor Cells

INDEX OF TABLES

  • TABLE 2.1: Potential CAR-T Targeted Antigens Present on Hematological Malignant Cells
  • TABLE 2.2: Key Differences between the Available Vectors
  • TABLE 2.3: The 11 CAR-T Cell Therapies Available in the Global Market
  • TABLE 2.4: Common Toxicities Associated with CAR-T Treatment
  • TABLE 3.1: Strategies for Future CAR-T Therapies
  • TABLE 3.2: A Sample of CAR-T Studies on Solid Tumors
  • TABLE 3.3: New Target Antigens and New Target Cancers
  • TABLE 3.4: A sample of Allogeneic CAR-T Studies
  • TABLE 4.1: History of Development of CAR-T Cell Therapy
  • TABLE 4.2: Approved CAR-T Products, their Developers and Indications
  • TABLE 4.3: Upcoming CAR-T Stars
  • TABLE 4.4: Cancer Population Addresses by CAR-T Therapy
  • TABLE 6.1: CAR-T Target Antigens in Hematological Cancers
  • TABLE 6.2: Targeted Antigens involved in the Approved CAR-Ts
  • TABLE 7.1: Geographical Distribution of CAR-T Patents, March 2024
  • TABLE 7.2: Top Ten Applicants for CAR-T Patents, March 2024
  • TABLE 7.3: Top Ten Inventors of CAR-T Patents, March 2024
  • TABLE 7.4: Top Ten Owners of CAR-T Patents, March 2024
  • TABLE 7.5: Legal Status of CAR-T Patent Applications, March 2024
  • TABLE 8.1: CAR-T Clinical Trials by Country, March 2024
  • TABLE 8.2: Number of CAR-T Clinical Trials by Funding Type, March 2024
  • TABLE 8.3: Clinical Trials Focusing on Solid Tumors by Country, March 2024
  • TABLE 8.4: CAR-T Solid Tumor Clinical Trials by Phase of Study, March 2024
  • TABLE 8.5: Funding Types in CAR-T Solid Tumor Clinical Trials, March 2024
  • TABLE 8.6: Percent Biomarker Distribution in CAR-T Clinical Trials
  • TABLE 8.7: CAR-T Targeted Indications in the U.S. Clinical Trials
  • TABLE 8.8: Indications Addressed by CAR-T Clinical Trials in China
  • TABLE 8.9: CAR-T Clinical Trial Sponsor Companies and Institutions in the U.S.
  • TABLE 8.10: CAR-T Clinical Trial Sponsor Companies and Institutions in China
  • TABLE 8.11: CAR-T Clinical Trial Sponsor Companies and Institutions in Other Countries
  • TABLE 8.12: Clinical Trials of 4th, 5th gen. and Gene Edited CAR-Ts
  • TABLE 9.1: NIH Funding for CAR-T Research, 2024
  • TABLE 10.1: CAR-T Venture Capital Funding, 2014-March 2024
  • TABLE 10.2: IPO Invested in CAR-T Companies, 2014-March 2024
  • TABLE 10.3: CAR-T Licensing Deals, 2015-March 2024
  • TABLE 10.4: CAR-T Collaboration Deals Signed between 2013 and March 2024
  • TABLE 10.5: CAR-T Merger and Acquisition (M&A) Deals, 2015-March 2024
  • TABLE 10.6: Overview of CAR-T Funding, 2014-March 2024
  • TABLE 11.1: List Prices of CAR-T Cells
  • TABLE 11.2: Pre-, Peri-, and Post Infusion Unit Costs
  • TABLE 11.3: Adverse Events Rates and Unit Costs of Management
  • TABLE 11.4: Reimbursement for CAR-T Cases, FY 2023 vs. FY 2024
  • TABLE 11.5: Cost of CAR-T cell Products in the EU Countries
  • TABLE 11.6: Cost Components and Resource Use of Pre- and Post- CAR-T Cell Therapy
  • TABLE 11.7: Average Total Costs Pre- and Post- CAR-T Treatment in Former EU 5 and NL
  • TABLE 11.8: CAR-T Reimbursement Schemes in Europe
  • TABLE 12.1: FDA-Approved Therapies for R/R ALL Pediatric and Young Adult Patients
  • TABLE 12.2: FDA Approved Therapies for DLBCL
  • TABLE 12.3: FDA Approved Therapies for MCL
  • TABLE 12.4: FDA Approved Drugs for Multiple Myeloma
  • TABLE 12.5: FDA-Approved Drugs for Follicular Lymphoma
  • TABLE 12.6: Cost of Treating Blood Cancers
  • TABLE 13.1: Uptake of U.S. FDA-Approved CAR-Ts, 2017-2023
  • TABLE 13.2: Revenue Generation by CAR-T Therapy by Product, 2017-2023
  • TABLE 13.3: Estimated Modest Growth of CAR-T Cell Market by Product, 2023-2032
  • TABLE 13.4: Global Market for CAR-T Products by Geography, 2023-2032
  • TABLE 13.5: Global Market for CAR-T Therapies by Indication, 2024-2032
  • TABLE 14.1: AffyImmune's Affinity-Tuned Pipeline Products
  • TABLE 14.2: Aleta's CAR-T Engager Pipeline
  • TABLE 14.3: Allogene's AlloCAR-T Pipeline
  • TABLE 14.4: Anixa's CAR-T Pipeline
  • TABLE 14.5: Arbele's Advanced Cell Therapy Product Candidates
  • TABLE 14.6: ArcellX's Current Product Pipeline
  • TABLE 14.7: Atara's Product Pipeline
  • TABLE 14.8: Autolus' Therapies in Development
  • TABLE 14.9: Clinical & Preclinical Pipeline Overview
  • TABLE 14.10: Bellicum's Pipeline
  • TABLE 14.11: BRiDGECAR Program
  • TABLE 14.12: Cabaletta's Autoimmune Therapy Candidates in Development
  • TABLE 14.13: Carina's Clinical Programs
  • TABLE 14.14: CARsgen's Product Pipeline
  • TABLE 14.15: Cartesian's Product Pipeline
  • TABLE 14.16: Cellectis' Allogeneic CAR-T Cell Product Pipeline
  • TABLE 14.17: CRISPR Therapeutics' CAR-T Programs
  • TABLE 14.18: Elicera's Product Pipeline
  • TABLE 14.19: EXUMA's Pipeline Assets
  • TABLE 14.20: Galapagos' Oncology CAR-T Pipeline
  • TABLE 14.21: Gracell's Rich Product Pipeline
  • TABLE 14.22: IASO's Diverse Product Pipeline
  • TABLE 14.23: ImmPACT Bio's Product Pipeline
  • TABLE 14.24: Immuneels Product Pipeline
  • TABLE 14.25: JW Therapeutics' Product Pipeline
  • TABLE 14.26: Kite's Pipeline Cancer Therapies
  • TABLE 14.27: Product Pipeline to address Autoimmune Diseases
  • TABLE 14.28: Legend Biotech's Product Pipeline
  • TABLE 14.29: Leucid's Product Pipeline
  • TABLE 14.30: Luminary's Product Pipeline
  • TABLE 14.31: Lyell's Product Pipeline
  • TABLE 14.32: March Biosciences' Product Pipeline
  • TABLE 14.33: A Comparison Guide for MaxCyte's Electroporation Systems
  • TABLE 14.34: Minerva's CAR-T Pipeline Products for Solid Tumors
  • TABLE 14.35: Mustang's CAR-T Product Candidates
  • TABLE 14.36: Noile-Immune's PRIME-Based Product Pipeline
  • TABLE 14.37: Oxford Biomedica's CDMO Services
  • TABLE 14.38: PeproMene's Product Pipeline
  • TABLE 14.39: Poseida's CAR-T Product Pipeline
  • TABLE 14.40: Precigen's UltraCAR-T Pipeline
  • TABLE 14.41: Prescient's CAR-T Pruct Pipeline
  • TABLE 14.42: ProMabs CAR-T Cells
  • TABLE 14.43: ProMab's Discovery Services Plans & Prices
  • TABLE 14.44: Synthekine's Pipeline with SYNCAR-001 + STK-009
  • TABLE 14.45: T-CURX' Product Candidates in Clinical Trials
  • TABLE 14.46: Umoja's Product Pipeline
  • TABLE 14.47: Vor Biopharma's Current Product Pipeline
  • TABLE 14.48: Wugen's Product Pipeline
  • TABLE 14.49: Xenetic's CAR-T Product Pipeline